ANTH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANTH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Anthera Pharmaceuticals's Revenue for the three months ended in Mar. 2018 was $0.00 Mil. Anthera Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2018 was $6.24 Mil. Therefore, Anthera Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2018 was 0.00.
Asset Turnover is linked to ROE % through Du Pont Formula. Anthera Pharmaceuticals's annualized ROE % for the quarter that ended in Mar. 2018 was 181,741.18%. It is also linked to ROA % through Du Pont Formula. Anthera Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2018 was -494.97%.
The historical data trend for Anthera Pharmaceuticals's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anthera Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | |||||||||||
Asset Turnover | Get a 7-Day Free Trial | - | - | 0.12 | - | - |
Anthera Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | |
Asset Turnover | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Anthera Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Anthera Pharmaceuticals's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Anthera Pharmaceuticals's Asset Turnover falls into.
Asset Turnover measures how quickly a company turns over its asset through sales.
Anthera Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2017 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (A: Dec. 2017 ) | / | ( (Total Assets (A: Dec. 2016 ) | + | Total Assets (A: Dec. 2017 )) | / count ) |
= | 0 | / | ( (23.471 | + | 3.673) | / 2 ) |
= | 0 | / | 13.572 | |||
= | 0.00 |
Anthera Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2018 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (Q: Mar. 2018 ) | / | ( (Total Assets (Q: Dec. 2017 ) | + | Total Assets (Q: Mar. 2018 )) | / count ) |
= | 0 | / | ( (3.673 | + | 8.811) | / 2 ) |
= | 0 | / | 6.242 | |||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Anthera Pharmaceuticals (OTCPK:ANTH) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
Anthera Pharmaceuticals's annulized ROE % for the quarter that ended in Mar. 2018 is
ROE %** | (Q: Mar. 2018 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | -30.896 | / | -0.017 | ||
= | (Net Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (-30.896 / 0) | * | (0 / 6.242) | * | (6.242/ -0.017) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | % | * | 0 | * | -367.1765 |
= | ROA % | * | Equity Multiplier | ||
= | -494.97 % | * | -367.1765 | ||
= | 181,741.18 % |
Note: The Net Income data used here is four times the quarterly (Mar. 2018) net income data. The Revenue data used here is four times the quarterly (Mar. 2018) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Anthera Pharmaceuticals's annulized ROA % for the quarter that ended in Mar. 2018 is
ROA % | (Q: Mar. 2018 ) | ||
= | Net Income | / | Total Assets |
= | -30.896 | / | 6.242 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (-30.896 / 0) | * | (0 / 6.242) |
= | Net Margin % | * | Asset Turnover |
= | % | * | 0 |
= | -494.97 % |
Note: The Net Income data used here is four times the quarterly (Mar. 2018) net income data. The Revenue data used here is four times the quarterly (Mar. 2018) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Thank you for viewing the detailed overview of Anthera Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher S Henney | director | 10505 ROSELLE STREET, SAN DIEGO CA 92121 |
Shanahan William R Jr | officer: Chief Medical Officer | 10301 STELLA LINK HOUSTON TX 77025 |
Brian Mueller | director | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
Paul F Truex | director | PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502 |
Charles V Olson | officer: Chief Technology Officer | 25801 INDUSTRIAL BLVD., SUITE B, HAYWARD CA 94545 |
Klara Dickinson | officer: Chief Regulatory Officer | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Steven B Engle | director | C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710 |
James Pennington | officer: Interim Chief Medical Officer | 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545 |
Hislop Colin | officer: Chief Medical Officer | C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502 |
Sanford S Zweifach | director | 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021 |
Daniel K Spiegelman | director | MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003 |
Christopher P. Lowe | officer: CFO and Chief Business Officer | 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258 |
James Healy | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Orbimed Capital Gp Iv Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Samuel D Isaly | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By gurufocus 10qk • 05-14-2010
By gurufocus 10qk • 08-12-2010
By Marketwired Marketwired • 06-27-2018
By gurufocus 10qk • 11-12-2010
By Julie Young • 11-08-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.